Main Industry
Biotechnology
Main Product/Service
The company’s lead product, OBI‑858, is a novel 760 kDa botulinum toxin derived from Clostridium botulinum type A. OBI‑858 has successfully completed a Phase I clinical trial, demonstrating excellent safety, tolerability, and preliminary efficacy in reduc
Founded Year
2020
Unified Business No.
82943056
Status
Active
Number of Employees
0
Total Paid-in
Capital
1,069,247,500 (NT$)
Location of Company
Taiwan
, Hsinchu County
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Exclusive content for members
Members-only content. Please log in to access.
Introduction
OBIGEN Pharma, also known as Ding‑Jin Biotech, is the first Taiwan-based company dedicated to the research, development, and manufacturing of its own botulinum toxin products. The company operates under stringent safety and quality standards, maintaining
